-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Critical Analysis: IceCure Medical (NASDAQ:ICCM) & Titan Medical (NASDAQ:TMDI)
Critical Analysis: IceCure Medical (NASDAQ:ICCM) & Titan Medical (NASDAQ:TMDI)
Titan Medical (NASDAQ:TMDI – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Volatility and Risk
Titan Medical has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500.
Get Titan Medical alerts:Valuation & Earnings
This table compares Titan Medical and IceCure Medical's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Titan Medical | $20.09 million | 5.63 | -$14.86 million | ($0.19) | -5.32 |
| IceCure Medical | $4.14 million | 14.22 | -$9.90 million | ($0.45) | -2.87 |
Profitability
This table compares Titan Medical and IceCure Medical's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Titan Medical | N/A | -167.03% | -112.15% |
| IceCure Medical | -462.46% | -77.00% | -61.72% |
Analyst Ratings
This is a breakdown of current ratings for Titan Medical and IceCure Medical, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Titan Medical | 0 | 1 | 0 | 0 | 2.00 |
| IceCure Medical | 0 | 0 | 4 | 0 | 3.00 |
IceCure Medical has a consensus price target of $4.80, suggesting a potential upside of 272.09%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Titan Medical.
Institutional & Insider Ownership
3.6% of Titan Medical shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
IceCure Medical beats Titan Medical on 8 of the 13 factors compared between the two stocks.
About Titan Medical
(Get Rating)
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
About IceCure Medical
(Get Rating)
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.
Titan Medical (NASDAQ:TMDI – Get Rating) and IceCure Medical (NASDAQ:ICCM – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Titan Medical（纳斯达克股票代码：TMDI — 获取评级）和Icecure Medical（纳斯达克股票代码：ICCM — 获取评级）都是小型医疗公司，但哪家业务更好？我们将根据两家公司的收益、估值、机构所有权、风险、盈利能力、股息和分析师建议对比这两家公司。
Volatility and Risk
波动性和风险
Titan Medical has a beta of 2.15, meaning that its share price is 115% more volatile than the S&P 500. Comparatively, IceCure Medical has a beta of -0.22, meaning that its share price is 122% less volatile than the S&P 500.
Titan Medical的beta值为2.15，这意味着其股价的波动性比标准普尔500指数高115％。相比之下，Icecure Medical的beta值为-0.22，这意味着其股价的波动性比标准普尔500指数低122％。
Valuation & Earnings
估值与收益
This table compares Titan Medical and IceCure Medical's top-line revenue, earnings per share (EPS) and valuation.
该表比较了Titan Medical和IceCure Medical的最高收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Titan Medical | $20.09 million | 5.63 | -$14.86 million | ($0.19) | -5.32 |
| IceCure Medical | $4.14 million | 14.22 | -$9.90 million | ($0.45) | -2.87 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 泰坦医疗 | 2,09 万美元 | 5.63 | -1486 万美元 | (0.19 美元) | -5.32 |
| iCecure医疗 | 414 万美元 | 14.22 | -990 万美元 | (0.45 美元) | -2.87 |
Profitability
盈利能力
This table compares Titan Medical and IceCure Medical's net margins, return on equity and return on assets.
该表比较了Titan Medical和Icecure Medical的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Titan Medical | N/A | -167.03% | -112.15% |
| IceCure Medical | -462.46% | -77.00% | -61.72% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 泰坦医疗 | 不适用 | -167.03% | -112.15% |
| iCecure医疗 | -462.46% | -77.00% | -61.72% |
Analyst Ratings
分析师评级
This is a breakdown of current ratings for Titan Medical and IceCure Medical, as provided by MarketBeat.com.
这是Marketbeat.com提供的Titan Medical和Icecure Medical当前评级的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Titan Medical | 0 | 1 | 0 | 0 | 2.00 |
| IceCure Medical | 0 | 0 | 4 | 0 | 3.00 |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 泰坦医疗 | 0 | 1 | 0 | 0 | 2.00 |
| iCecure医疗 | 0 | 0 | 4 | 0 | 3.00 |
IceCure Medical has a consensus price target of $4.80, suggesting a potential upside of 272.09%. Given IceCure Medical's stronger consensus rating and higher probable upside, analysts clearly believe IceCure Medical is more favorable than Titan Medical.
Icecure Medical的共识目标价为4.80美元，这表明潜在的上涨空间为272.09％。鉴于IceCure Medical的共识评级更高，可能的上行空间也更高，分析师显然认为IceCure Medical比泰坦医疗更有利。
Institutional & Insider Ownership
机构所有权和内部所有权
3.6% of Titan Medical shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
泰坦医疗3.6％的股份由机构投资者持有。强大的机构所有权表明，捐赠基金、大型基金经理和对冲基金认为，从长远来看，公司的表现将超过市场。
Summary
摘要
IceCure Medical beats Titan Medical on 8 of the 13 factors compared between the two stocks.
比较两只股票的13个因素中，IceCure Medical在8个因素上击败了Titan Medical。
About Titan Medical
关于泰坦医疗
(Get Rating)
（获取评分）
Titan Medical Inc., a medical technology company, focuses on the development and commercialization of robotic assisted surgical technologies for application in minimally invasive surgery. It is developing the Enos system, a robotic single access surgical system that includes a surgeon-controlled patient cart comprising a 3D high-definition vision system and multi-articulating instruments for performing surgical procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during surgical procedures. The company is headquartered in Toronto, Canada.
Titan Medical Inc. 是一家医疗技术公司，专注于应用于微创手术的机器人辅助手术技术的开发和商业化。它正在开发Enos系统，这是一种机器人单通道手术系统，包括由外科医生控制的患者推车，包括用于进行外科手术的三维高清视觉系统和多关节仪器；以及外科医生工作站，为外科医生提供与患者推车的人体工程学接口，并在外科手术期间提供患者体内的三维内窥镜视图。该公司总部位于加拿大多伦多。
About IceCure Medical
关于 iceCure Med
(Get Rating)
（获取评分）
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
IceCure Medical Ltd是一家医疗器械公司，从事用于冷冻消融（冻结）人体肿瘤的医疗器械的研究、开发和商业化。它提供ProSense系统，一种用于治疗乳腺肿瘤的冷冻消融解决方案。该公司成立于2006年，总部位于以色列凯撒利亚。
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收《泰坦医学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Titan Medical及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧